Likewise, others have demonstrated that pretreatment IFNγ-related immune gene signatures predicted response to anti-PD-1 therapy in head and neck squamous cell carcinoma, gastric cancer, and melanoma [48, 49, 51]. The gene discussed is IFNG; the disease is head and neck squamous cell carcinoma.